Sana Biotechnology Inc Ordinary Shares SANA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SANA is a good fit for your portfolio.
News
-
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
-
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
-
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
-
Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Sana Biotechnology Announces Pricing of Upsized Public Offering
-
Sana Biotechnology Announces Proposed Public Offering of Common Stock
Trading Information
- Previous Close Price
- $7.73
- Day Range
- $7.25–7.84
- 52-Week Range
- $2.75–12.00
- Bid/Ask
- $7.61 / $7.68
- Market Cap
- $1.68 Bil
- Volume/Avg
- 3.4 Mil / 2.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 328
- Website
- https://www.sana.com
Comparables
Valuation
|
Metric
|
SANA
|
SLRN
|
CELC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.32 | 0.73 | 2.99 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SANA
|
SLRN
|
CELC
|
|---|---|---|---|
Quick Ratio | 3.18 | 8.53 | 12.78 |
Current Ratio | 3.31 | 8.65 | 13.43 |
Interest Coverage | — | — | −12.43 |
Quick Ratio
SANA
SLRN
CELC
Profitability
|
Metric
|
SANA
|
SLRN
|
CELC
|
|---|---|---|---|
Return on Assets (Normalized) | −45.68% | −57.50% | −35.57% |
Return on Equity (Normalized) | −81.96% | −88.66% | −49.08% |
Return on Invested Capital (Normalized) | −66.18% | −96.26% | −39.21% |
Return on Assets
SANA
SLRN
CELC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wfrbbbnlk | Wpbc | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fqfhppth | Rtftk | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jlkgdcjn | Jfnwpf | $98.1 Bil | |
MRNA
| Moderna Inc | Pgvfmkjq | Bydyx | $39.1 Bil | |
ARGX
| argenx SE ADR | Xktpvtnk | Lsqp | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Hybrqdqh | Dhvy | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vtwwxzlh | Hmdqyk | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kjkfvyb | Pkmgnb | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Djslvyzlc | Dydyzk | $12.5 Bil | |
INCY
| Incyte Corp | Lxsznwtw | Tjfdgn | $11.9 Bil |